» Articles » PMID: 27644231

Prostate Cancer Trends in Asia

Overview
Journal World J Urol
Specialty Urology
Date 2016 Sep 21
PMID 27644231
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Differences in the incidence and mortality rates for prostate cancer between East and West are clearly defined, with higher rates in the West and lower rates in the East. Treatment methods are generally selected in accordance with general practice guidelines, but the current reality in Asia is that there is not sufficient clinical data to set Asia-specific guidelines for treatment. This leads to a situation whereby for the large part guidelines based on scientific evidence accumulated in Western countries are followed, but from time to time cases are encountered when such guidelines may not be considered to be the most appropriate for the case at hand.

Methods And Results: Although there is a relatively large volume of clinical evidence relating to endocrine therapy in Asia, the treatment choices and effects differ to those in the West. These regional differences are thought to be due to various factors, including not only differences in genetic background, but also distinct differences in the living and healthcare environments. If the differences between East and West in terms of trends in prostate cancer could be examined, with positive aspects being adopted and negative aspects being improved, this could also be expected to be of use in developing a better treatment strategy for prostate cancer. The exchanging of information on a broader, global level will enable improvements in prevention, diagnosis and treatment of prostate cancer.

Conclusion: It is in pursuit of this objective that it is important to promote high-quality clinical trials and joint epidemiological studies in Asia and work to accumulate data that are comparable to data available in Western countries.

Citing Articles

Predictive value of volumetric parameters based on F-PSMA-1007 PET/CT for prostate cancer metastasis.

Li Y, Chen J, Wang X, Yang P, Yang J, Zhao Q Front Oncol. 2024; 14:1335205.

PMID: 38469242 PMC: 10925687. DOI: 10.3389/fonc.2024.1335205.


Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy.

Fujimoto A, Sakamoto S, Horikoshi T, Zhao X, Yamada Y, Rii J Sci Rep. 2023; 13(1):10079.

PMID: 37344491 PMC: 10284848. DOI: 10.1038/s41598-023-36685-1.


Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer.

Baba H, Sakamoto S, Zhao X, Yamada Y, Rii J, Fujimoto A Cancers (Basel). 2022; 14(23).

PMID: 36497304 PMC: 9740872. DOI: 10.3390/cancers14235823.


The Asia-Pacific AMS800 artificial urinary sphincter consensus statement.

Chung E, Liao L, Kim J, Wang Z, Kitta T, Lin A Int J Urol. 2022; 30(2):128-138.

PMID: 36375037 PMC: 10100264. DOI: 10.1111/iju.15083.


Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.

Daouk R, Bahmad H, Saleh E, Monzer A, Ballout F, Kadara H PLoS One. 2020; 15(8):e0237442.

PMID: 32790767 PMC: 7425932. DOI: 10.1371/journal.pone.0237442.


References
1.
Cooperberg M, Hinotsu S, Namiki M, Ito K, Broering J, Carroll P . Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009; 27(26):4306-13. PMC: 2744272. DOI: 10.1200/JCO.2008.21.5228. View

2.
Kitagawa Y, Ueno S, Izumi K, Kadono Y, Mizokami A, Hinotsu S . Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer. World J Urol. 2015; 34(3):319-27. DOI: 10.1007/s00345-015-1621-5. View

3.
Akaza H, Kim C, Carroll P, Choi I, Chung B, Cooperberg M . Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int. 2015; 2(2):50-69. PMC: 4099396. DOI: 10.12954/PI.14047. View

4.
Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T . Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004; 34(2):86-9. DOI: 10.1093/jjco/hyh015. View

5.
Cooperberg M, Hinotsu S, Namiki M, Carroll P, Akaza H . Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2014; 117(1):102-9. DOI: 10.1111/bju.12937. View